Expression of matrix metalloproteinases 2, 7 and 9 in patients with colorectal cancer

Elena Kostova; Maja Slaninka - Miceska; Nikola Labacevski; Krume Jakovski; Jasmina Trojachanec; Emilija Atanasovska; Vlado Janevski; Rubens Jovanovik; Vesna Janevska

doi:10.2298/3149

Elena Kostova Department of Preclinical and Clinical Pharmacology and Toxicology, Faculty of Medicine, Ss.Cyril and Methodius University
Maja Slaninka - Miceska Department of Preclinical and Clinical Pharmacology and Toxicology, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of Macedonia
Nikola Labacevski Department of Preclinical and Clinical Pharmacology and Toxicology, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of Macedonia
Krume Jakovski Department of Preclinical and Clinical Pharmacology and Toxicology, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of Macedonia
Jasmina Trojachanec Department of Preclinical and Clinical Pharmacology and Toxicology, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of Macedonia
Emilija Atanasovska Department of Preclinical and Clinical Pharmacology and Toxicology, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of Macedonia
Vlado Janevski Digestive Surgery Clinic, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of Macedonia
Rubens Jovanovik Department of Pathology, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of Macedonia
Vesna Janevska Department of Pathology, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of Macedonia

DOI: https://doi.org/10.2298/3149

Keywords: colorectal neoplasms, matrix metalloproteinases, neoplasm staging, immunohistochemistry, sensitivity and specificity,

Abstract

Background/Aim. Matrix metalloproteinases (MMPs) are perceived to play a key role in tumor invasion and metastasis by their capacity to degrade basement membranes and extracellular matrix proteins. The aim of this study was to investigate the expressions of MMP-2, MMP-7 and MMP-9 in tumor tissue and their relation to clinicopathologic features in patients with colorectal cancer. Methods. Specimens of resected colorectal cancer and surrounding normal tissue of 82 patients were immunohistochemically stained for MMP-2, MMP-7 and MMP-9. The results of immunohistochemical expression of MMPs were correlated with some clinical and pathologic parameters. Results. Immunohistochemical expression of MMP-2 was more frequent in the patients with higher preoperative serum levels of carcinoembryonic antigen (CEA) (p = 0.047), MMP-2 (p = 0.018), MMP-9 (p = 0.036) and in those with lymph node metastasis (p=0.018) and the advanced stage of the disease (p = 0.046). Expression of MMP-7 was more frequent in the patients with elevated preoperative serum levels of: CEA (p = 0.012), MMP-7 (p = 0.036), MMP-9 (p = 0.023) and with deeply invasive neoplasms (p = 0.027). MMP-9 cell expression was in a positive correlation with elevated preoperative serum levels of: CEA (p = 0.013), MMP-2 (p = 0.012), MMP-9 (p = 0.018) and depth of CRC invasion, ie T-parameter (p = 0.027). Conclusion. Immunohistochemical expression of MMPs is a useful indicator of the disease development and progression in patients with colorectal cancer.

References

Ferlay J, Parkin DM, Steliarova-Fiocher E. Estimates of cancer in-cidence and mortality in Europe in 2008. Eur J Cancer 2010; 46(4): 765−81.

Sun X, Zhang H. Clinicopathological significance of stromal variables: angiogenesis, lymphangiogenesis, inflammatory infil-tration, MMP and PINCH in colorectal carcinomas. Molecular Cancer 2006; 5(1): 43.

Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clinl Oncol 2009; 27(31): 5287−97.

Basset P, Okada A, Chenard MP, Kannan R, Stoll I, Anglard P, et al. Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. Matrix Biol 1997; 15(8−9): 535−41.

Hong SW, Kang YK, Lee B, Lee WY, Jang YG, Paik IW, et al. Matrix metalloproteinase-2 and -7 expression in colorectal cancer. J Korean Soc Coloproctol 2011; 27(3): 133−9.

Herszényi L, Hritz I, Lakatos G, Varga MZ, Tulassay Z. The be-havior of matrix metalloproteinases and their inhibitors in co-lorectal cancer. Int J Mol Sci 2012; 13(10): 13240−63.

Yang B, Su K, Gao J, Rao Z. Expression and Prognostic Value of Matrix Metalloproteinase-7 in Colorectal Cancer. Asian Pa-cific J Cancer Prev 2012; 13(3): 1049−52.

Leeman MF, Curran S, Murray GI. New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol 2003; 201(4): 528−34.

Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999; 274(31): 21491−4.

Liabakk NB, Talbot I, Smith RA, Wilkinson K, Balkwill F. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res. 1996; 56(1): 190−6.

Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y. Role of Matrix Metalloproteinase-7 (Matrilysin) in Human Cancer In-vasion, Apoptosis, Growth, and Angiogenesis. Exp Biol Med J 2006; 231(1): 20−7.

Pesta M, Topolcan O, Holubec L, Rupert K, Cerna M, Holubec SL, et al. Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples. Anticancer Res 2007; 27(4A): 1863−7.

Bendardaf R, Lamlum H, Pyrhönen S. Prognostic and predictive molecular markers in colorectal carcinoma. Anticancer Res 2004; 24(4): 2519−30.

Vihinen P, Kähäri V. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. International jour-nal of cancer. Int J Cancer 2002; 99(2): 157−66.

Zlobec I, Lugli A. Prognostic and predictive factors in colorectal cancer. Postgrad Med J 2008; 84(994): 403−11.

O'Jessica B, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edi-tion staging. J Natl Cancer Inst 2004; 96(19): 1420−5.

Ishida H, Murata N, Tada M, Okada N, Hashimoto D, Kubota S, et al. Determining the Levels of Matrix Metalloproteinase-9 in Portal and Peripheral Blood is Useful for Predicting Liver Me-tastasis of Colorectal Cancer. Jpn J Clin Oncol 2003; 33(4): 186−91.

Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Can-cer Invest 2005; 23(4): 338−51.

Mroczko B, Groblewska M, Okulczyk B, Kedra B, Szmitkowski M. The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients. Int J Colorectal Dis 2010; 25(10): 1177−84.

Yukawa N, Yoshikawa T, Akaike M, Sugimasa Y, Takemiya S, Yanoma S, et al. Plasma concentration of tissue inhibitor of matrix metalloproteinase 1 in patients with colorectal carci-noma. Br J Surg 2001; 88(12): 1596−601.

Illemann M. Histological Studies of Extracellular Matrix De-grading Proteases in Primary Colon Adenocarcinomas and Their Liver Metastases [dissertation]. Copenhagen: University of Copenhagen; 2008.

Pasternak B. Towards surgical use of matrix metalloproteinase biology [dissertation]. Linköping: Linköping University; 2008.

Liotta LA, Rao CN, Barsky SH. Tumor invasion and the ex-tracellular matrix. Lab. Invest 1983; 49(6): 636−49.

Tryggvason K. The laminin family. Curr Opin. Cell Biol 1993; 5(5): 877−82.

Poulsom R, Pignatelli M, Stetler-Stevenson WG, Liotta LA, Wright PA, Jeffery RE, et al. Stromal expression of 72 kda type IV col-lagenase (MMP-2) and TIMP-2 mRNAs in colorectal neopla-sia. Am J Pathol 1992; 141(2): 389−96.

Poulsom R, Hanby AM, Pignatelli M, Jeffery RE, Longcroft JM, Rogers L, et al. Expression of gelatinase A and TIMP-2 mRNAs in desmoplastic fibroblasts in both mammary carcinomas and basal cell carcinomas of the skin. J Clin Pathol 1993; 46(5): 429−36.

Maatta M. Role of basement membranes and their break-down in human carcinomas. A study by in situ hybridization and immunohistochemistry of the expression of laminin chains, matrix metalloproteinases (MMPs) and their tissue inhibitors of metalloproteinases [dissertation]. Oulu: University of Oulu; 2000.

Parsons SL, Watson SA, Collins HM, Griffin NR, Clarke PA, Steele RJ. Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy. Br J Cancer 1998; 78(11): 1495−502.

Tutton MG, George ML, Eccles SA, Burton S, Swift IR, Abulafi MA. Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients. International journal of cancer. Int J Cancer 2003; 107(4): 541−50.

Ruokolainen H. The Prognostic Role of Matrix Metallopro-teinase-2 and -9 (MMP-2, MMP-9) and their Tissue Inhibitors -1 and -2 (TIMP-1, TIMP-2) in Head and Neck Squamous cell Carcinoma [dissertation]. Oulu: University of Oulu; 2005.

Dragutinović VV, Radonjić NV, Petronijević ND, Tatić SB, Dimitri-jević IB, Radovanović NS, et al. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) in preoperative serum as independ-ent prognostic markers in patients with colorectal cancer. Mol Cell Biochem 2011; 355(1−2): 173−8.

Maurel J, Nadal C, Garcia-Albeniz X, Gallego R, Carcereny E, Al-mendro V, et al. Serum matrix metalloproteinase 7 levels identi-fies poor prognosis advanced colorectal cancer patients. Inter-national journal of cancer. Int J Cancer 2007; 121(5): 1066−71.

Kim TS, Kim YB. Correlation between expression of matrix metalloproteinase-2 (MMP-2), and matrix metalloproteinase-9 (MMP-9) and angiogenesis in colorectal adenocarcinoma. J. Korean Med Sci 1999; 14(3): 263−70.

Li B, Zhao P, Liu S, Yu Y, Han M, Wen J. Matrix metallopro-teinase-2 and tissue inhibitor of metallo-proteinase-2 in colo-rectal carcinoma invasion and metastasis. World J Gastroen-terol 2005; 11(20): 3046−50.

Cho YR, Kwon H, Suh S, Lee JH, Kim S, Choi H, et al. Expres-sions of matrix metalloproteinase-7 and -9 and their prognos-tic significances in rectal cancer. Cancer Res Treat 2005; 37(6): 354−9.

Schwandner O, Schlamp A, Broll R, Bruch HP. Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer. Int J Colorectal Dis 2007; 22(2): 127−36